<p>Sight Sciences, Inc.（纳斯达克股票代码：SGHT - 获取免费报告）内部人士 Jeremy Hayden 于 1 月 6 日（星期二）出售了 1,785 股该公司的股票。股票的平均售价为 7.48 美元，总价值为 13,351.80 美元。出售后，该内部人士持有 245,420 股公司的股票，估值约为 1,835,741.60 美元。这笔交易代表其持股比例下降了 0.72%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
<p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
<h2>Sight Sciences 价格表现</h2>
<p>在周二的午盘交易中，纳斯达克 SGHT 的股票下跌了 0.24 美元，跌至 7.47 美元。该股票的交易量为 197,717 股，而其平均交易量为 290,394 股。该公司的速动比率为 8.93，流动比率为 9.60，债务与股本比率为 0.62。该股票的 50 日简单移动平均为 7.52 美元，200 日简单移动平均为 5.13 美元。该公司的市值为 3.9494 亿美元，市盈率为-8.30，贝塔值为 2.42。Sight Sciences, Inc.的 1 年最低价为 2.03 美元，1 年最高价为 9.24 美元。</p>
<p>Sight Sciences（纳斯达克：SGHT - 获取免费报告）最近于 9 月 8 日（星期三）发布了季度财报。该公司报告本季度每股收益（EPS）为-0.81 美元。本季度的收入为 1254 万美元。Sight Sciences 的股本回报率为-61.59%，净利润率为-60.63%。卖方分析师平均预计 Sight Sciences, Inc.在当前财政年度将发布-0.99 的每股收益。</p>
<h2>关键的 Sight Sciences 新闻</h2>
<p>以下是本周影响 Sight Sciences 的关键新闻：</p>
<ul>
<li>积极情绪：Piper Sandler 将 Sight Sciences 的评级从中性上调至增持，这一买方分析师的升级可能会吸引投资者的兴趣和购买动能。Piper Sandler 升级</li>
<li>中性情绪：尽管近期有销售，内部人士仍持有大量股份——首席执行官 Paul Badawi（约 590 万股）和首席技术官 David Badawi（约 190 万股）保留了大量持股，这可能表明他们与长期价值的一致性，即使他们在减持股份。内部持股披露</li>
<li>消极情绪：高管的集中内部出售——首席执行官 Paul Badawi、首席技术官 David Badawi、首席财务官 James Rodberg、高级副总裁 Brenton Taylor 和内部人士 Jeremy Hayden 在 1 月 2 日至 6 日之间进行了集中出售。这些交易的总披露销售额约为 48 万美元；每笔销售占卖方持股的比例较小（&lt;1%），但集中时机可能对股票造成下行压力。请参见首席执行官/高管的披露。首席执行官销售披露首席技术官销售披露其他内部披露</li>
</ul>
<h2>分析师升级和降级</h2>
<p>几家券商最近对 SGHT 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Sight Sciences 股票的 “卖出（e+）” 评级。Lake Street Capital 在 10 月 21 日的报告中将 Sight Sciences 的目标价格从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 12 月 2 日的研究报告中将 Sight Sciences 的目标价格从 6.00 美元上调至 8.00 美元，并给予该公司 “持平” 评级。花旗集团在 12 月 11 日的研究报告中将 Sight Sciences 的目标价格从 5.50 美元上调至 9.10 美元，并给予该股票 “中性” 评级。最后，Raymond James Financial 在周一的研究报告中设定了 Sight Sciences 的目标价格为 9.00 美元。四位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 8.30 美元。</p>
<p><strong>获取我们最新的 Sight Sciences 股票分析</strong></p>
<h2>机构投资者对 Sight Sciences 的看法</h2>
<p>一些机构投资者最近对该股票的持仓进行了调整。BNP Paribas Financial Markets 在第三季度将其在 Sight Sciences 的持股增加了 99.8%。BNP Paribas Financial Markets 现在拥有 7,579 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 3,785 股。CWM LLC 在第二季度将其在 Sight Sciences 的持股增加了 70.2%。CWM LLC 现在拥有 7,607 股该公司的股票，价值 31,000 美元，此前在该期间增持了 3,137 股。Tower Research Capital LLC TRC 在第二季度将其在 Sight Sciences 的持股增加了 32.7%。Tower Research Capital LLC TRC 现在拥有 11,665 股该公司的股票，价值 48,000 美元，此前在上个季度增持了 2,875 股。蒙特利尔银行在第二季度收购了 Sight Sciences 的新股份，价值约 49,000 美元。最后，R Squared Ltd 在第三季度购买了 Sight Sciences 的新股份，价值约 64,000 美元。目前，55.51% 的股票由机构投资者和对冲基金持有。</p>
<h2>Sight Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sight Sciences, Inc.是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的技术。该公司的旗舰产品包括 OMNI®外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare®系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
<p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Sight Sciences</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>崩盘前一个月</li>
<li>BNZI：随着人工智能营销推动创纪录收入，BNZI 领先</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到联邦影响</li>
<li>标普 8000</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
<p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Sight Sciences 并不在名单上。</p>
<p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SGHT

<p>杰里米·海登（Jeremy Hayden），Sight Sciences, Inc.（纳斯达克代码：SGHT）的内部人士，出售了 1,785 股，平均价格为 7.48 美元，总计 13,351.80 美元。出售后，他仍持有 245,420 股，估值约为 184 万美元，持股比例下降了 0.72%。该交易已向美国证券交易委员会（SEC）披露。Sight Sciences 的股票交易价格下跌至 7.47 美元，市值为 3.9494 亿美元。分析师们的看法不一，派珀·桑德勒（Piper Sandler）将该股票评级上调至 “增持”，而韦斯评级（Weiss Ratings）则维持 “卖出” 评级。平均目标价格为 8.30 美元，四位分析师给予 “买入” 评级</p>

<p>Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 1,785 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $7.48, for a total value of $13,351.80. Following the sale, the insider owned 245,420 shares of the company's stock, valued at approximately $1,835,741.60. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Sight Sciences, Inc.（纳斯达克股票代码：SGHT - 获取免费报告）内部人士 Jeremy Hayden 于 1 月 6 日（星期二）出售了 1,785 股该公司的股票。股票的平均售价为 7.48 美元，总价值为 13,351.80 美元。出售后，该内部人士持有 245,420 股公司的股票，估值约为 1,835,741.60 美元。这笔交易代表其持股比例下降了 0.72%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
</div><h2>Sight Sciences Price Performance</h2>
<div class="lb-trans"><h2>Sight Sciences 价格表现</h2>
</div><p>Shares of NASDAQ SGHT traded down $0.24 during midday trading on Tuesday, hitting $7.47. The stock had a trading volume of 197,717 shares, compared to its average volume of 290,394. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $5.13. The company has a market capitalization of $394.94 million, a PE ratio of -8.30 and a beta of 2.42. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克 SGHT 的股票下跌了 0.24 美元，跌至 7.47 美元。该股票的交易量为 197,717 股，而其平均交易量为 290,394 股。该公司的速动比率为 8.93，流动比率为 9.60，债务与股本比率为 0.62。该股票的 50 日简单移动平均为 7.52 美元，200 日简单移动平均为 5.13 美元。该公司的市值为 3.9494 亿美元，市盈率为-8.30，贝塔值为 2.42。Sight Sciences, Inc.的 1 年最低价为 2.03 美元，1 年最高价为 9.24 美元。</p>
</div><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The firm had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. On average, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sight Sciences（纳斯达克：SGHT - 获取免费报告）最近于 9 月 8 日（星期三）发布了季度财报。该公司报告本季度每股收益（EPS）为-0.81 美元。本季度的收入为 1254 万美元。Sight Sciences 的股本回报率为-61.59%，净利润率为-60.63%。卖方分析师平均预计 Sight Sciences, Inc.在当前财政年度将发布-0.99 的每股收益。</p>
</div><h2>Key Sight Sciences News</h2>
<div class="lb-trans"><h2>关键的 Sight Sciences 新闻</h2>
</div><p>Here are the key news stories impacting Sight Sciences this week:</p>
<div class="lb-trans"><p>以下是本周影响 Sight Sciences 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade</li>
<li>Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing</li>
<li>Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (&lt;1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filingCTO sale filingOther insider filings</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Piper Sandler 将 Sight Sciences 的评级从中性上调至增持，这一买方分析师的升级可能会吸引投资者的兴趣和购买动能。Piper Sandler 升级</li>
<li>中性情绪：尽管近期有销售，内部人士仍持有大量股份——首席执行官 Paul Badawi（约 590 万股）和首席技术官 David Badawi（约 190 万股）保留了大量持股，这可能表明他们与长期价值的一致性，即使他们在减持股份。内部持股披露</li>
<li>消极情绪：高管的集中内部出售——首席执行官 Paul Badawi、首席技术官 David Badawi、首席财务官 James Rodberg、高级副总裁 Brenton Taylor 和内部人士 Jeremy Hayden 在 1 月 2 日至 6 日之间进行了集中出售。这些交易的总披露销售额约为 48 万美元；每笔销售占卖方持股的比例较小（&lt;1%），但集中时机可能对股票造成下行压力。请参见首席执行官/高管的披露。首席执行官销售披露首席技术官销售披露其他内部披露</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several brokerages recently issued reports on SGHT. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Sight Sciences in a research note on Monday, December 29th. Lake Street Capital boosted their target price on Sight Sciences from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, October 21st. Morgan Stanley upped their price target on Sight Sciences from $6.00 to $8.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Citigroup lifted their price objective on Sight Sciences from $5.50 to $9.10 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, December 11th. Finally, Raymond James Financial set a $9.00 price objective on Sight Sciences in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $8.30.</p>
<div class="lb-trans"><p>几家券商最近对 SGHT 发布了报告。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Sight Sciences 股票的 “卖出（e+）” 评级。Lake Street Capital 在 10 月 21 日的报告中将 Sight Sciences 的目标价格从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 12 月 2 日的研究报告中将 Sight Sciences 的目标价格从 6.00 美元上调至 8.00 美元，并给予该公司 “持平” 评级。花旗集团在 12 月 11 日的研究报告中将 Sight Sciences 的目标价格从 5.50 美元上调至 9.10 美元，并给予该股票 “中性” 评级。最后，Raymond James Financial 在周一的研究报告中设定了 Sight Sciences 的目标价格为 9.00 美元。四位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 8.30 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Sight Sciences</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Sight Sciences 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Sight Sciences</h2>
<div class="lb-trans"><h2>机构投资者对 Sight Sciences 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock worth $26,000 after acquiring an additional 3,785 shares during the last quarter. CWM LLC increased its stake in Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company's stock worth $31,000 after purchasing an additional 3,137 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock worth $48,000 after purchasing an additional 2,875 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Sight Sciences during the second quarter worth about $49,000. Finally, R Squared Ltd purchased a new position in shares of Sight Sciences in the third quarter valued at approximately $64,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对该股票的持仓进行了调整。BNP Paribas Financial Markets 在第三季度将其在 Sight Sciences 的持股增加了 99.8%。BNP Paribas Financial Markets 现在拥有 7,579 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 3,785 股。CWM LLC 在第二季度将其在 Sight Sciences 的持股增加了 70.2%。CWM LLC 现在拥有 7,607 股该公司的股票，价值 31,000 美元，此前在该期间增持了 3,137 股。Tower Research Capital LLC TRC 在第二季度将其在 Sight Sciences 的持股增加了 32.7%。Tower Research Capital LLC TRC 现在拥有 11,665 股该公司的股票，价值 48,000 美元，此前在上个季度增持了 2,875 股。蒙特利尔银行在第二季度收购了 Sight Sciences 的新股份，价值约 49,000 美元。最后，R Squared Ltd 在第三季度购买了 Sight Sciences 的新股份，价值约 64,000 美元。目前，55.51% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Sight Sciences Company Profile</h2>
<div class="lb-trans"><h2>Sight Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.</p>
<div class="lb-trans"><p>Sight Sciences, Inc.是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的技术。该公司的旗舰产品包括 OMNI®外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare®系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
</div><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p>
<div class="lb-trans"><p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A month before the crash</li>
<li>BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>S&amp;P 8000</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Sight Sciences</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>崩盘前一个月</li>
<li>BNZI：随着人工智能营销推动创纪录收入，BNZI 领先</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到联邦影响</li>
<li>标普 8000</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Sight Sciences 并不在名单上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Jeremy Hayden 出售了 1,785 股 Sight Sciences（纳斯达克代码：SGHT）的股票